Poor
Not Aligned
Patient Risk:
High
Summary
Substantial portions of the extracted claims are not supported by the provided FDA label excerpts, particularly those asserting alcohol-specific risks, quantitative alcohol limits, and detailed counseling instructions. One claim is contradicted by the provided contraindications section (severe liver disease contraindication).
Category Scores
Accurate Statements
Vascepa belongs to omega-3-related chemistry (icosapent ethyl is an ethyl ester of omega-3 fatty acid EPA).
Section 11 (Description): “Icosapent ethyl is an ethyl ester of the omega-3 fatty acid eicosapentaenoic acid (EPA).”
Vascepa has a mechanism involving hepatic triglyceride/VLDL-TG synthesis and/or secretion reduction and triglyceride clearance, including reduced lipogenesis and inhibition of DGAT.
Section 12.1 (Mechanism of Action): “EPA reduces hepatic VLDL-TG synthesis and/or secretion…”, and lists “inhibition of… DGAT; decreased lipogenesis in the liver…”.
Vascepa is associated with increased bleeding risk, with higher incidence in patients receiving concomitant antithrombotic medications (e.g., aspirin, clopidogrel, warfarin).
Section 5.3 (Bleeding): provides comparative bleeding event rates and states incidence is greater with concomitant antithrombotic medications.
Patients receiving Vascepa and concomitant anticoagulants and/or antiplatelet agents should be monitored for bleeding.
Section 7.1 (Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents): “Monitor patients… for bleeding.”
In hepatic impairment, ALT and AST should be monitored periodically during therapy with Vascepa.
Section 8.7 (Hepatic Impairment): “ALT and AST levels should be monitored periodically during therapy with VASCEPA.”
Vascepa counseling includes that it may increase risk for atrial fibrillation or atrial flutter, and may increase risk for bleeding especially with other antithrombotic agents.
Section 17 (Patient Counseling Information): statements about atrial fibrillation/atrial flutter risk and bleeding risk, especially with other antithrombotic agents.
Vascepa capsules should be swallowed whole; do not break open, crush, dissolve, or chew.
Section 17: “Advise patients to swallow VASCEPA capsules whole. Do not break open, crush, dissolve, or chew…”
Unsupported Statements
Combining Vascepa with alcohol can increase the risk of adverse effects (and related alcohol-coadministration risk claims).
No provided label excerpts discuss alcohol use with Vascepa.
Alcohol can increase the risk of bleeding by thinning the blood.
No provided label excerpts discuss alcohol and bleeding.
When combined with Vascepa, bleeding risk may be increased, particularly in patients taking anticoagulant medications (framed as alcohol-Vascepa combination).
Label supports bleeding risk with concomitant antithrombotic medications but does not mention alcohol.
Both Vascepa and alcohol can cause liver damage when consumed in excess; combination may increase risk of liver injury including acute liver failure.
No provided label excerpts discuss alcohol-related liver damage or acute liver failure.
Alcohol can increase blood pressure and heart rate and cardiac workload; combination may exacerbate cardiovascular workload; may increase risk of cardiovascular events such as heart attacks and strokes (alcohol-specific).
No provided label excerpts discuss alcohol physiologic effects or alcohol-related cardiovascular event risk.
Citations to studies in the Journal of Clinical Lipidology and Journal of Cardiovascular Medicine about Vascepa+alcohol risks.
No provided label excerpts cite these journals or those alcohol-specific findings.
Alcohol coadministration is particularly hazardous in patients with pre-existing liver disease.
No provided label excerpts link alcohol coadministration to hepatic risk.
Alcohol coadministration is particularly hazardous in patients taking anticoagulant medications.
No provided label excerpts mention alcohol.
Regularly checking liver function tests can help ensure that the liver is not being damaged by the combination of Vascepa and alcohol.
Label supports ALT/AST monitoring in hepatic impairment during Vascepa therapy, but not the purpose or any alcohol combination.
Informing a healthcare provider immediately if bleeding, nausea, or vomiting occurs is recommended when taking Vascepa with alcohol.
No provided label excerpts give alcohol-specific counseling or immediate-reporting instruction for nausea/vomiting.
Avoid consuming more than one drink per day for women and two drinks per day for men while taking Vascepa.
No provided label excerpts provide any alcohol quantity limits.
An occasional glass of wine is unlikely to cause harm when taking Vascepa.
No provided label excerpts provide guidance about wine/occasional alcohol.
Regular consumption of alcohol with Vascepa may increase the risk of adverse effects.
No provided label excerpts discuss alcohol consumption with Vascepa.
Vascepa may interact with certain antidepressants.
No provided label excerpts mention antidepressant interactions.
Stopping Vascepa abruptly can lead to adverse effects, including increased triglyceride levels.
No provided label excerpts address abrupt discontinuation or rebound triglyceride effects.
Signs of liver damage may include nausea, vomiting, abdominal pain, fatigue, and jaundice.
No provided label excerpts list these specific symptoms as “signs of liver damage” for Vascepa.
If signs of liver damage occur, patients should seek medical attention immediately.
No provided label excerpts provide this immediate-care instruction.
Contradictions
High
AI Statement
Vascepa may be contraindicated in patients with severe liver disease.
Label Reference
Section 4 (Contraindications) provided excerpt: contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to Vascepa or its components. No severe liver disease contraindication shown in provided excerpts.
Important Omissions
Label-supported indication details are not reflected in the extracted claim beyond a general “high triglyceride levels” statement (e.g., adjunct to maximally tolerated statin therapy to reduce risk of MI/stroke/coronary revascularization/unstable angina requiring hospitalization in specific adult populations, and adjunct to diet for severe hypertriglyceridemia).
Importance:
Moderate
If the query involves alcohol-related safety, the label excerpt provided does not support alcohol-specific counseling; the AI extract should have limited claims to on-label bleeding risk with concomitant antithrombotic agents and hepatic impairment monitoring during therapy (rather than adding alcohol-specific hazards).
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The extracted claims introduce multiple alcohol-coadministration safety assertions (bleeding, liver injury/acute liver failure, cardiovascular events, quantitative drink limits) that are not supported by the provided FDA label excerpts, and include an incorrect contraindication statement for severe liver disease.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple alcohol-related and study-citation claims are not supported by the provided label excerpts; one contraindication claim is contradicted by the provided contraindications section.
Suggested Improvement
Remove or rephrase all alcohol-specific safety, quantitative drink-limit, and study-citation claims unless supported by the provided label. Limit on-label safety statements to those explicitly supported (increased bleeding risk with concomitant anticoagulant/antiplatelet/antithrombotic therapy; ALT/AST monitoring in hepatic impairment; hypersensitivity contraindication).